Table 4.
Multivariate analyses for RFS and OS in patients with pathological stage I adenocarcinoma
| Variables | RFS | OS | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Age at operation (year) | ||||
| <70 | 1 | |||
| ≥70 | — | — | 2.39 (1.09–5.24) | 0.029 |
| Serum CEA (ng/mL) | ||||
| ≤5 | 1 | 1 | ||
| >5 | 1.11 (0.53–2.33) | 0.776 | 1.74 (0.79–3.81) | 0.163 |
| SUVmax of primary tumor | ||||
| ≤2.3 | 1 | 1 | ||
| >2.3 | 5.31 (2.06–13.65) | 0.001 | 3.31 (1.36–8.05) | 0.008 |
| Pleural invasion | ||||
| Absent | 1 | |||
| Present | 1.46 (0.57–3.76) | 0.429 | — | — |
| Pathological stage | ||||
| Stage IA | 1 | |||
| Stage IB | 1.17 (0.53–2.55) | 0.697 | — | — |
CEA, carcinoembryonic antigen; CI, confidence interval; HR, hazard ratio; OS, overall survival; RFS, recurrence‐free survival; SUVmax, maximum standardized uptake value.